Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592337 | 1.00 | NAPRT (0.67) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3150862 | 0.94 | NAPRT (0.60) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8126157 | 0.88 | NAPRT (0.53) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1742846 | 0.84 | NAPRT (0.53) | NAPRTDGAT1RAB9ASMN1; SMN2ALDH1A1 | |
| Morpholine SCHEMBL27536575 | 0.82 | NAPRT (0.47) | NAPRTDGAT1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5272361 | 0.82 | NAPRT (0.59) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL7440808 | 0.82 | NAPRT (0.72) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL17801 | 0.82 | NAPRT (0.72) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL29760376 | 0.82 | NAPRT (0.72) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A | |
| 6-Chloronicotinic Acid SCHEMBL17541528 | 0.81 | NAPRT (0.92) | NAPRTDGAT1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 992 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62238264-A | — | — | None | — | — | JP | disclosed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026098548-A1 | PROTEIN DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF, AND METHOD | 四川科伦博泰生物医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4658659-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-0105053-B1 | ARALKYLAMINOETHANOL HETEROCYCLIC COMPOUNDS | MERCK & CO. INC. (US) | 1988-01-20 | — | — | EP | disclosed |
| JP-S62238264-A | 2-HALO-5-ACETYLPYRIDINE | NIPPON TOKUSHU NOYAKU SEIZO KK | 1987-10-19 | — | — | JP | disclosed |
| US-4686222-A | ADRENERGIC BLOCKERS, BRONCHODILATORS | MERCK & CO., INC. (US) | 1987-08-11 | — | — | US | disclosed |
| EP-0214158-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
| EP-0192060-A1 | Heterocyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1986-08-27 | — | — | EP | disclosed |
| WO-1986004582-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1986-08-14 | — | — | WO | disclosed |
| US-4568679-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE AGENTS, BRONCHODILATOR AGENTS, REDUCING INTRAOCULAR PRESSURE | MERCK & CO., INC. (US) | 1986-02-04 | — | — | US | disclosed |
| EP-0105053-A1 | Aralkylaminoethanol heterocyclic compounds | MERCK & CO. INC. (US) | 1984-04-11 | — | — | EP | disclosed |
| US-4358455-A | GLAUCOMA, HYPOTENSIVE, ANTIARRHYTHMIA, BRONCHODILATORS | MERCK & CO., INC. (US) | 1982-11-09 | — | — | US | disclosed |
| US-4348396-A | Substituted 11-oxo-11H-pyrido[2,1-b]quinazolines and method of inhibiting allergic reactions with them | HOFFMANN-LA ROCHE INC. (US) | 1982-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NAPRT 1634/4885DGAT1 2919/4885RAB9A 4270/4885 |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | NAPRT 4105/4885DGAT1 4593/4885RAB9A 1986/4885 |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | NAPRT 1912/4885DGAT1 1756/4885RAB9A 445/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | NAPRT 1912/4885DGAT1 1756/4885RAB9A 445/4885 |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KIT, LTK, HRH3 | NAPRT 4108/4885DGAT1 3161/4885RAB9A 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.